CDK4 and breast cancer: Palbociclib was originally reported in 2009 as PD032991 and noted to selectively inhibit cyclin-dependent kinases 4 and 6, which resulted in selective inhibition of the proliferation of luminal ER positive breast cancer cell lines, while non-luminal basal cell lines were largely resistant to treatment.